The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease (Q39663434)

13 September 2017

title

The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease (English)

1 reference

13 September 2017

Emanuela Lacaná

1

1 reference

13 September 2017

Lynne P Yao

series ordinal

2

1 reference

13 September 2017

Anne R Pariser

series ordinal

3

1 reference

13 September 2017

Amy S Rosenberg

series ordinal

4

1 reference

13 September 2017

publication date

17 January 2012

1 reference

American Journal of Medical Genetics Part C: Seminars in Medical Genetics

13 September 2017

published in

1 reference

13 September 2017

volume

160C

1 reference

13 September 2017

issue

1

1 reference

13 September 2017

page(s)

30-39

1 reference

Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Pompe disease gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Immunomics: discovering new targets for vaccines and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Neural deficits contribute to respiratory insufficiency in Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Mannose 6-phosphate receptors: new twists in the tale

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Antibody-mediated regulation of the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Immunomodulatory gene therapy in lysosomal storage disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Dilative arteriopathy and basilar artery dolichoectasia complicating late-onset Pompe disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Late-onset acid maltase deficiency associated with intracranial aneurysm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Epoetin-associated pure red cell aplasia: past, present, and future considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Elimination of antibodies to recombinant enzyme in Pompe's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Fc-receptors as regulators of immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand...

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

CRIM-negative infantile Pompe disease: 42-month treatment outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Identification of two subtypes of infantile acid maltase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

A randomized study of alglucosidase alfa in late-onset Pompe's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

The natural course of non-classic Pompe's disease; a review of 225 published cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

Pompe disease: Design, methodology, and early findings from the Pompe Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.C.31316

21 January 2018

Identifiers

DOI

10.1002/AJMG.C.31316

1 reference

13 September 2017

1 reference